- Report
- August 2024
- 60 Pages
Global
From €1341EUR$1,500USD£1,158GBP
- Report
- June 2024
- 200 Pages
Global
From €7108EUR$7,950USD£6,136GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4426EUR$4,950USD£3,821GBP
- Report
- February 2024
- 117 Pages
Global
From €4247EUR$4,750USD£3,666GBP
- Report
- February 2025
- 150 Pages
Global
From €3576EUR$3,999USD£3,087GBP
- Report
- May 2024
- 140 Pages
Global
From €3576EUR$3,999USD£3,087GBP
- Report
- July 2024
- 100 Pages
Global
From €3353EUR$3,750USD£2,895GBP
- Report
- May 2025
- 225 Pages
Global
From €2235EUR$2,500USD£1,930GBP
- Report
- January 2025
- 19 Pages
Global
From €16090EUR$17,995USD£13,890GBP
- Report
- January 2025
- 162 Pages
Global
From €16090EUR$17,995USD£13,890GBP
- Report
- December 2024
- 49 Pages
Global
From €3572EUR$3,995USD£3,084GBP
- Drug Pipelines
- May 2023
- 151 Pages
Global
From €13408EUR$14,995USD£11,574GBP
- Report
- November 2022
- 330 Pages
Global
From €3577EUR$4,000USD£3,087GBP
- Report
- May 2020
- 218 Pages
Global
From €13408EUR$14,995USD£11,574GBP
- Report
- May 2020
- 47 Pages
Global
From €3572EUR$3,995USD£3,084GBP
- Report
- June 2025
- 150 Pages
Global
From €4337EUR$4,850USD£3,744GBP
- Report
- March 2026
- 150 Pages
Germany
From €4337EUR$4,850USD£3,744GBP
- Report
- March 2026
- 150 Pages
China
From €4337EUR$4,850USD£3,744GBP
- Report
- March 2026
- 150 Pages
India
From €4337EUR$4,850USD£3,744GBP
- Report
- March 2026
- 150 Pages
Canada
From €4337EUR$4,850USD£3,744GBP
![Loading Indicator](/images/loading.gif")
The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more
![911±¬ÁÏÍø](/images/logo.svg"){kind=logo}
![911±¬ÁÏÍø](/images/logo-research-and-markets-print.png"){kind=logo}